Back
  1. Home
  2. Profile of Laurence PIRSON (ULiège)
Profil

PIRSON Laurence

Unilab > Discipline Biologie Clinique (Chimie Médicale, Toxicologie Clinique, Médicolégale, de l'Environnement et en Entreprise, Hématologie et Microbiologie Médicale)

See author's contact details
Main Referenced Co-authors
Baron, Frédéric  (8)
Beguin, Yves  (8)
Gothot, André  (7)
Giet, Olivier  (6)
Meuris, Nathalie  (6)
Main Referenced Keywords
Animals (1); Antigens, CD/metabolism (1); Apoptosis/drug effects (1); Bcr-Abl (1); Blood Cells/drug effects (1);
Main Referenced Disciplines
Hematology (8)
Pharmacy, pharmacology & toxicology (4)
Engineering, computing & technology: Multidisciplinary, general & others (1)

Publications (total 13)

The most downloaded
171 downloads
Pirson, L.* , Baron, F.* , Meuris, N., Giet, O., Castermans, E., Greimers, R., Di Stefano, I., Gothot, A., & Beguin, Y. (2006). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice. Stem Cells, 24 (7), 1814-21. doi:10.1634/stemcells.2005-0290 https://hdl.handle.net/2268/6956

The most cited

13 citations (Scopus®)

Pirson, L.* , Baron, F.* , Meuris, N., Giet, O., Castermans, E., Greimers, R., Di Stefano, I., Gothot, A., & Beguin, Y. (2006). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice. Stem Cells, 24 (7), 1814-21. doi:10.1634/stemcells.2005-0290 https://hdl.handle.net/2268/6956

Widart, J., Beauvois, V., Dumont, F., LASRI, S., LAMBERT, V., PIRSON, L., & Hubert, P. (2016). Réseau Qualité des Laboratoire de l'ULg - Rapport d'activité Février 2016.

Pirson, L. (10 September 2010). Recherche de traces de production de drogues de synthèse dans les eaux usées : projet GEOAMP [Paper presentation]. Journal Club (Service de Toxicologie du CHU de Liège), Liège, Belgium.

Pirson, L. (09 October 2009). Dosage de l'alcool dans le cadre de la sécurité routière : approche statistique [Paper presentation]. Journal Club (Service de Toxicologie du CHU de Liège), Liège, Belgium.

Denooz, R., & Pirson, L. (February 2009). Gestion du contrôle de qualité interne [Paper presentation]. Formation continue en Toxicologie, Belgium.

Pirson, L. (05 September 2008). Biomarqueurs en toxicologie: ADN oxydé et adduits à l'ADN [Paper presentation]. Journal Club (Service de Toxicologie du CHU de Liège), Liège, Belgium.

Pirson, L.* , Baron, F.* , Meuris, N., Giet, O., Castermans, E., Greimers, R., Di Stefano, I., Gothot, A., & Beguin, Y. (2006). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice. Stem Cells, 24 (7), 1814-21. doi:10.1634/stemcells.2005-0290
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Pirson, L., Baron, F., Gothot, A., & Beguin, Y. (2006). Impact of Imatinib on immune function in vitro [Poster presentation]. 21th general meeting of the Belgian Hematological Society, Brussels, Belgium.

Pirson, L., Baron, F., Meuris, N., Giet, O., Castermans, E., Greimers, R., Di Stefano, I., Gothot, A., & Beguin, Y. (2005). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDBeta2mNull [Poster presentation]. 20th general meeting of the Belgian Hematological Society, Brussels, Belgium.

Pirson, L., Baron, F., Giet, O., Meuris, N., Bours, V., Fillet, G., Gothot, A., & Beguin, Y. (2004). The tyrosine kinase inhibitor Imatinib increases irradiation toxicity but does not impair engraftment of human CD34+ cells into NOD/SCIDB2mNull mice [Poster presentation]. 19th general meeting of the Belgian Hematological Society, Brussels, Belgium.

Pirson, L., Baron, F., Giet, O., Meuris, N., Bours, V., Fillet, G., Gothot, A., & Beguin, Y. (2003). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor STI571 does not impair engraftment of human CD34+ cells into NOD/SCIDB2mNull mice [Poster presentation]. 32nd annual meeting of the International Society of Experimental Hematology, Paris, France.

Pirson, L., Baron, F., Giet, O., Meuris, N., Bours, V., Fillet, G., Gothot, A., & Beguin, Y. (2003). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor STI571 does not impair engraftment of human CD34+ cells into NOD/SCIDB2mNull mice [Poster presentation]. 18th general meeting of the Belgian Hematological Society, Brussels, Belgium.

Humblet-Baron, S., Baron, F., Pirson, L., Beguin, Y., & Fillet, G. (28 August 2002). Traitement moléculaire du cancer: le STI571, un inhibiteur des tyrosines kinases. Revue Médicale Suisse, 60 (598), 1504-1508.
Peer Reviewed verified by ORBi

Pirson, L., Baron, F., Giet, O., Meuris, N., Bours, V., Fillet, G., Gothot, A., & Beguin, Y. (2002). Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibior STI571 does not impair engraftment of human CD34+ cells into NOD/SCIDB2mNull mice [Poster presentation]. 44th annual meeting and exposition of American Society of Hematology, Philadelphia, United States.

Contact ORBi